ArticleResearch and practice in thrombosis and haemostasis2018
Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review.
Article in Research and practice in thrombosis and haemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus.Current oncology (Toronto, Ont.) · 2021Pooled it
- Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Balancing Thrombosis and Bleeding: Antithrombotic Therapy in Cirrhosis-Related Thrombocytopenia.Journal of clinical medicine · 2026Review
- Direct oral anticoagulants in thrombocytopenic patients with cancer.Research and practice in thrombosis and haemostasis · 2026Article
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- Acute Myeloid Leukemia Associated With Catastrophic Arterial and Venous Thrombi.JACC. Case reports · 2025Article
- STARTing to bridge the evidence gap: management of cancer-associated thrombosis with concomitant thrombocytopenia.Research and practice in thrombosis and haemostasis · 2025Article
- Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis (START): design and rationale of the START pilot randomized controlled trial.Research and practice in thrombosis and haemostasis · 2025Article
- Atrial Fibrillation in Patients with Breast Cancer: A Literature Review.Cardiology and therapy · 2025Review
- Impact of thrombocytopenia on bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis.Blood advances · 2024Article
- Treatment of VTE in the thrombocytopenic cancer patient.Hematology. American Society of Hematology. Education Program · 2024Review
- An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.Current oncology reports · 2023Review
- How to approach acute thrombosis and thrombocytopenia.Clinical medicine (London, England) · 2023Review
- Incidental right atrial mass in a patient with secondary pancreatic cancer: A case report and review of literature.World journal of clinical cases · 2023Article
- Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia.Hematology. American Society of Hematology. Education Program · 2022Article
- Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients' and Clinicians' Awareness.Life (Basel, Switzerland) · 2022Review
- Screening, Diagnosis and Management of Atrial Fibrillation in Cancer Patients: Current Evidence and Future Perspectives.Arquivos brasileiros de cardiologia · 2022Review
- EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.HemaSphere · 2022Article
- Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter-related thrombosis.Research and practice in thrombosis and haemostasis · 2022Article
- Challenging issues in the management of cancer-associated venous thromboembolism.Blood research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe management of anticoagulation for cancer-associated thrombosis (CAT) in patients with thrombocytopenia is controversial. Whereas some studies suggest that administration of reduced-dose low-molecular-weight heparin (LMWH) or temporary discontinuation for moderate and severe thrombocytopenia may be a safe and effective, others suggest full-dose anticoagulation with transfusion support. We sought to address this important knowledge gap and summarize the literature comparing these two common management strategies.
methodsA systematic review of the literature (PROSPERO CRD42017077127) using MEDLINE (inception to September 2017) was conducted. We included studies that reported recurrent venous thromboembolism (VTE) and major bleeding complications among patients treated with both of the two most common management strategies: therapeutic anticoagulation with platelet transfusion support and dose-modified anticoagulation for periods when the platelet count is <50 × 10
resultsA total of 134 article records were identified on the initial search and 10 articles underwent full text review. Two observational studies met the inclusions criteria. A total of 121 patients with CAT and thrombocytopenia were included. Forty-two of these patients had pulmonary embolism and 87 had deep vein thrombosis (DVT) including 38 upper extremity DVT. Overall, 27% of patients, regardless of their treatment strategy, experienced recurrent VTE. Thirteen percent of anticoagulated patients (15% of all patients) experienced a major bleeding episode. Meta-analysis could not be conducted.
conclusionsOur findings do not support one management strategy over another to treat CAT patients with thrombocytopenia. However, the data highlights the heightened risk of recurrent VTE in this patient population despite the thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.